medigraphic.com
Asociación Mexicana de Gastroenterología

2006, Number 2

<< Back Next >>

Rev Gastroenterol Mex 2006; 71 (2)

American Gastroenterological Association Technical Review on the Management of Hepatitis C

Dienstag JL, Mchutchison JG

Language: Spanish
References: 374
Page: 198-236
PDF size: 304.14 Kb.


Text Extraction

No abstract


REFERENCES

  1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.

  2. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437-55.

  3. World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.

  4. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin C, Cristianini G, Dionysos Study Group. Prevalence of chronic liver disease in the general population of northern Italy: the dionysos study. Hepatology 1994; 20: 1442-9.

  5. Kim WR, Gross JB Jr, Poterucha JJ, Locke GR III, Dickson ER. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology 2001; 33: 201-6.

  6. Detre KM, Belle SH, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepat Rev 1997; 2: 219-28.

  7. Féray C, Gigou M, Sameul D, Paradis V, Wilber J, David MF, Urdea M, Reynes M, Brechot C, Bismuth H. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 1137-43.

  8. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.

  9. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-9.

  10. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36(Suppl. 1): S30-S34.

  11. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-42.

  12. Davis GL, Albright JE, Cook SE, Rosenberg D. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.

  13. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo Q-L, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-500.

  14. Donahue JG, Munoz A, Ness PM, Brown DEJ, Yawn DH, McAllister HAJ, Reitz BA, Nelson KE. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369-73.

  15. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infection. N Engl J Med 1996; 334: 1685-90.

  16. Aach RD, Stevens CE, Hollinger FB, Mosley JW, Peterson DA, Taylor PE, Johnson RG, Barbosa LH, Nemo GJ. Hepatitis C virus infection in post-transfusion hepatitis: an analysis with first- and second-generation assays. N Engl J Med 1991; 325: 1325-9.

  17. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S-9S.

  18. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001; 33: 321-7.

  19. Stramer SL, Glynn SA, Kleinman SH, Strong M, Caglioti S, Wright DJ, Dodd RY, Busch MP, National Heart Lung and Blood Institute Nucleic Acid Test Study Group. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351: 760-8.

  20. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82.

  21. Buti M, San Miguel R, Brosa M, Cabasés JM, Medina M, Casado MA, Fosbrook L, Esteban R. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42: 639-45.

  22. American Gastroenterological Association. Position and policy statement: policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995; 108: 925-6.

  23. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998; 47: 1-39.

  24. National Institutes of Health Consensus Development Conference. Management of hepatitis C. Hepatology 1997; 26(Suppl. 1): 1S-156S.

  25. Consensus statement. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999; 30: 956-61.

  26. National Institutes of Health Consensus Development Conference statement. management of hepatitis C: 2002-June 10- 12, 2002. Hepatology 2002; 36(Suppl 1): S3-S20.

  27. U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med 2004; 140: 462-4.

  28. Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140: 465-79.

  29. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16.

  30. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.

  31. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, Kruska L, Hensel F, Petry W, Haussinger D. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.

  32. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40.

  33. Matsumara H, Moriyama K, Goto I, Okubo J, Arakawa T. Natural course of progression of fibrosis in Japanese patients with chronic liver disease type C-a study of 527 patients at one establishment. J Viral Hepat 2000; 7: 268-75.

  34. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88: 240-3.

  35. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Al-masio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.

  36. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26(Suppl. 1): 34S-38S.

  37. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36(Suppl. 1): S74-S83.

  38. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-675.

  39. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-8.

  40. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.

  41. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  42. Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer HJ, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.

  43. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992; 15: 1013-16.

  44. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-7.

  45. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.

  46. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 1999; 116: 378-86.

  47. Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, Marcellin P, Balart L, Alberti A, Craxì A. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39: 333-42.

  48. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M, IHIT Study Group. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-81.

  49. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomised trial of effects of interferon-_ on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.

  50. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483-91.

  51. NHS Center for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD guidelines for those carrying out or commissioning reviews. CRD report #4. York: University of York; 1996.

  52. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35.

  53. Hoofnagle J. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26(Suppl. 1): 15S-20S.

  54. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(Suppl. 1): S35-S46.

  55. Vogt M, Lang T, Frosner G, Klinger C, Sendl AF, Zeller A, Wiebecke B, Langer B, Meisner H, Hess J. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866-70.

  56. Kenny-Walsh E, Irish Hepatology Research Group. Clinical out-comes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228-33.

  57. Wiese M, Berr F, Lafrenz M, Porast H, Oesen U, East German Hepatitis C Study Group. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000; 32: 91-6.

  58. Bjøro K, Frøland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1607-11.

  59. Poynard T, Bedossa P, Opolon P, OBSVIRC, METAVIR, CLINIVIR, DOSVIRC Groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.

  60. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36(Suppl. 1): S47-S56.

  61. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.

  62. Lagging LM, Westin J, Svensson E, Aires N, Dhillon AP, Lindh M, Wejstal R, Norkrans G. Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 2002; 22: 136-44.

  63. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, Conjeevaram HS, Sallie R, Di Bisceglie AM, Hepatitis C Study Group. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995; 123: 330-7.

  64. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, Puel J, Pascal JP, Duffaut M, Abbal M. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113: 1675-81.

  65. Kuzushita N, Hayashi N, Moribe T, Katayama K, Kanto T, Nakatani S, Kaneshige T, Tatsumi T, Ito A, Mochizuki K, Sasaki Y, Kasahara A, Hori M. Influence of HLA haplotypes on the clinical course of individuals infected with hepatitis C virus. Hepatology 1998; 27: 240-4.

  66. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyen-decker O, Boitnott J, Wilson LE, Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-6.

  67. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.

  68. Hourigan LF, MacDonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-19.

  69. Alberti A, Benvegnù L. Management of hepatitis C. J Hepatol 2003; 38(Suppl. 1): S104-S118.

  70. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors for liver fibrosis in hepatitis C virus infected patients. J Hepatol 2001; 34: 730-9.

  71. Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, Wiselka M, Norris S. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52: 1035-40.

  72. Negro F. Hepatitis C virus and liver steatosis: when fat is not beautiful. J Hepatol 2004; 40: 533-5.

  73. Martin P, Di Bisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JH. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 1989; 97: 1559-61.

  74. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.

  75. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.

  76. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, Rey C, Abad MA, Rodríguez M, Sales Gilabert M, Gonzalez F, Miron P, Caruz A, Relimpio F, Torronteras R, Leal M, Lissen E. Human immunodeficiency virus infection modifies the natural history of parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.

  77. Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African-Americans: summary of a workshop. Gastroenterology 2000; 119: 1385-96.

  78. Crosse K, Umeadi OG, Anania FA, Laurin J, Papadimitriou J, Drachenberg C, Howell CD. Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clin Gastroenterol Hepatol 2004; 2: 463-8.

  79. Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, Shiffman ML. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004; 2: 469-73.

  80. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744-9.

  81. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-40.

  82. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, Mondelli MU. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25: 754-8.

  83. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.

  84. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36(Suppl. 1): S152-S160.

  85. Strader DB. Understudied populations with hepatitis C. Hepatology 2002; 36(Suppl. 1): S226-S236.

  86. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002; 36(Suppl. 1): S210-S219.

  87. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002; 36(Suppl. 1): S220-S225.

  88. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, Poynard T. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine aminotransferase activity. Hepatology 1998; 27: 868-72.

  89. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, Palmentieri B, Sasso FC, Torella R. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760-4.

  90. Martinon-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, Levy S, Degott C, Valla DC, Marcellin P. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34: 1000-5.

  91. Wali M, Lewis S, Hubscher S, Harrison R, Ahmed M, Elias E, Mutimer D. Histologic progression during short-term follow-up of patients with chronic hepatitis C virus infection. J Viral Hepat 1999; 6: 445-52.

  92. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36(Suppl. 1): S179-S184.

  93. Ahmed A, Keeffe EB. Chronic hepatitis C with normal aminotransferase levels. Gastroenterology 2004; 126: 1409-15.

  94. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36(Suppl. 1): S65-S73.

  95. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2003; 122: 1554-68.

  96. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.

  97. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63.

  98. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS, Choo QL, Colombo M, Cuypers HTM, Date T, Dusheiko GM, Esteban JI, Fay O, Hadziyannis SJ, Han J, Hatzakis A, Holmes EC, Hotta H, Houghton M, Irvine B, Kohara M, Kolberg JA, Kuo G, Lau JYN, Lelie PN, Maertens G, McOmish F, Miyamura T, Mizokami M, Nomoto A, Prince AM, Reesink HW, Rice C, Roggendorf M, Schalm SW, Shikata T, Shimotohno K, Stuyver L, Trepo C, Weiner A, Yap PL, Urdea MS. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.

  99. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-83.

  100. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36(Suppl. 1): S21-S29.

  101. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 346-55.

  102. el-Zayadi A, Selim O, Haddad S, Simmonds P, Hamdy H, Badran HM, Shawky S. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital J Gastroenterol Hepatol 1999; 31: 472-5.

  103. Koshy A, Marcellin P, Martinot M, Madda JP. Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver 2000; 20: 335-9.

  104. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RNM, Phillips MJ, Port-mann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H. Histologic grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.

  105. Bedossa P, Poynard T, French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hepatology 1994; 24: 289-93.

  106. Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis 2000; 20: 47-55.

  107. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000; 133: 665-75.

  108. Cadranel JF, Rufat P, Degos F, The Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Practices of liver biopsy in France: results of a prospective nationwide sur-vey. Hepatology 2000; 32: 477-81.

  109. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-44.

  110. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, Heaton S, Conrad A, Pockros PJ, McHutchison JG. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90.

  111. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837-42.

  112. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HCJ, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van-Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-6.

  113. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-10.

  114. Niederau C, Heintges T, Haussinger D. Treatment of chronic hepatitis C with a-interferon: an analysis of the literature. Hepatogastroenterology 1996; 43: 1544-56.

  115. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.

  116. Carithers RLJ, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26(Suppl. 1): 83S-88S.

  117. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26: 961-6.

  118. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon alpha therapy. Ann Intern Med 1997; 127: 875-81.

  119. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid M, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998; 28: 1121-7.

  120. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-8.

  121. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney M, Hoofnagle JH. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903.

  122. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 473–7.

  123. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995; 46: 43-7.

  124. Reichard O, Norkrans G, Fryden A, Braconier J-H, Sonnerborg A, Weiland O, Swedish Study Group. Randomized, double-blind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.

  125. Lai M-Y, Kao J-H, Yang P-M, Wang J-T, Chen P-J, Chan K-W, Chu J-S, Chen D-S. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-12.

  126. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling M-H, Cort S, Albrecht JA, Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.

  127. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J, International Hepatitis Interventional Therapy Group (IHIT). Randomized trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.

  128. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Lellicelli A, Grisorio B, Barbarini G. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. J Hepatol 2000; 33: 448-55.

  129. Pol S, Nalpas B, Bourliere M, Couzigou P, Tran A, Abergel A, Zarski JP, Berthelot P, Brechot C. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C. Hepatology 2000; 31: 1338-44.

  130. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 2001; 323: 1151-5.

  131. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55.

  132. Fang SH, Hwang LH, Chen DS, Chiang BL. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 levels. J Hepatol 2000; 33: 791-8.

  133. Reichard O, Schvarc R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 1997; 26(Suppl. 1): 108S-111S.

  134. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, Ding JW, Liu MF, Rotstein O, Phillips MJ, Levy G. Ribavirin inhibits viral-induced macrophage production of tumor necrosis factor, interleukin-1, and procoagulant fg12 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160: 3487-93.

  135. Hong Z. The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact? Hepatology 2003; 38: 807-10.

  136. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-9.

  137. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001; 98: 6895-900.

  138. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JYN, Hong Z, Andino R, Cameron CE. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6: 1375-9.

  139. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002; 76: 8505-17.

  140. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L, Dhumeaux D. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126: 703-14.

  141. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432: 922-4.

  142. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O’Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.

  143. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.

  144. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP III, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, De Pamphilis J. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.

  145. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.

  146. Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P, Shiffman ML, Minuk G, Reddy KR, Reindollar RW, Lin A, Brunda MJ, PEGASYS International Study Group. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004; 99: 1298-305.

  147. FDA advisory documents for PEG-IFN alfa-2b and PEG-IFN alfa-2a. Available at: http://www.fda.gov/ohrms/dockets/ac/01/ transcripts/3819t1.htm and http://www.fda.gov/chrms/dock-ets/ ac/02/transcripts/3909t1.htm. Accessed August 16, 2005.

  148. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay K, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK, International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in geno-type-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.

  149. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, Sarrazin C, Harvey J, Brass C, Albrecht J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.

  150. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zachini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.

  151. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 1998; 282: 103-7.

  152. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245-52.

  153. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alfa-2a. Gastroenterology 2001; 120: 1438-47.

  154. Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, Esteban R. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35: 930-6.

  155. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37: 1343-50.

  156. Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36(Suppl 1): S145-S151.

  157. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997; 26: 1187-99.

  158. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J, PEG-FIBROSIS Project Group. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.

  159. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, Luketic VA, Sanyal AJ, Mills AS, Garrett CT. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26: 780-5.

  160. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, Ferreira-Gonzalez A, Mills AS, Garret C. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164-72.

  161. Knodell R, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.

  162. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, Park Y, Meschievitz C, Jones EA. Randomized, controlled trial of recombinant human a-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-25.

  163. McHutchison JG, Ware JEJ, Bayliss MS, Pianko S, Albrecht JK, Cort S, Yang I, Neary MP, Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. Hepatology 2001; 34: 140-7.

  164. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HCJ, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Martino FP, Sangvhi B, Albrecht J. Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther 1994; 16: 334-43.

  165. Bonkovsky HL, Woolley M, The Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999; 29: 264-70.

  166. Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004; 11: 148-56.

  167. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318-24.

  168. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-37.

  169. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-65.

  170. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A, Roda E. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141-7.

  171. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis C: a long-term observational study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.

  172. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593-602.

  173. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, Gebo KA. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002; 36(Suppl 1): S135-S144.

  174. Bernardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegnù L, Merkel C, Gatta A, Alberti A. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TTVH Study Group. Hepatogastroenterology 1999; 46: 3216-22.

  175. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, Solinas A, Brouwer JT, Thomas H, Realdi G, Corrocher R, Schalm SW, European Concerted Action on Viral Hepatitis (EUROHEP). Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997; 27: 201-5.

  176. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WL, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE, The HALT-C Trial Group. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-23.

  177. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36(Suppl 1): S237-S244.

  178. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht JA, International Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.

  179. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711-19.

  180. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, Park Y, Liang TJ, Hoofnagle JH. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273-9.

  181. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.

  182. Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1623-32.

  183. Dieterich DT, Wasserman R, Bräu N, Hassanein TI, Bibi EJ, Bowers PJ, Sulkowski MS. Once weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon a. Am J Gastroenterol 2003; 98: 2491-9.

  184. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37: 533-41.

  185. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ, The Proactive Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302-11.

  186. Wu JZ, Walker H, Lau JY, Hong Z. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother 2003; 47: 426-31.

  187. Watson J. Prospects for hepatitis C virus therapeutics: levovorin and viramidine as improved derivatives of ribavirin. Curr Opin Invest Drugs 2002; 3: 680-3.

  188. Gish R, Arora S, Nelson D, Fernandez H, Lamon K. Safety and efficacy of viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naïve patients (abstr). J Hepatol 2004; 40(Suppl 1): 141-2.

  189. Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clin Gastroenterol Hepatol 2004; 2: 183-97.

  190. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36 (Suppl 1): S185-S194.

  191. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-5.

  192. Everson G. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (low-accelerating-dose regimen) (abstr). Hepatology 2002; 36: 297A.

  193. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003; 9: S90-S94.

  194. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-15.

  195. Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, Garcia-Valdecasas JC, Navasa M, Rimola A, Rodes J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-96.

  196. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-62.

  197. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36(Suppl 1): S121-S127.

  198. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288-92.

  199. Shehab TM, Fontana RJ, Oberhelman K, Marrero JA, Su GL, Lok ASF. Effectiveness of interferon a-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol 2004; 2: 425-431.

  200. McHutchison J, Davis GL, Esteban-Mur R, Poynard T, Ling MH, Garaud JJ, Albrecht J. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alfa-2b alone or in combination with ribavirin (abstr). Hepatology 2001; 34: 244A.

  201. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26(Suppl 1): 57S-61S.

  202. Davis GL, Lindsay K, Albrecht J, Bodenheimer HC, Balart LA, Perrillo RP, Dienstag JL, Tamburro C, Schiff ER, Carey W, Payne J, Jacobson IM, Van Thiel DH, Lefkowitch J, Sanghvi B, Hepatitis Interventional Therapy Group. Clinical predictors of response to recombinant alpha interferon-a treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). J Viral Hepat 1994; 1: 55-63.

  203. Verbaan HP, Widell HE, Bondeson TL, Lindgren SC. High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin. Eur J Gastroenterol Hepatol 2002; 14: 627-33.

  204. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33: 704-7.

  205. Gordon SC, Fang JW, Silverman AL, McHutchison JG, Albrecht J. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to anti-viral therapy in chronic hepatitis C. Hepatology 2000; 32: 400-4.

  206. Lee SS, Sherman M. Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. J Viral Hepat 2001; 8: 202-5.

  207. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O’Brien CB, Lamour F, Lardelli P, PEGASYS Study NR16071 Investigator Group. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.

  208. Jacobson IM, Ahmed F, Russo MW, Lebovics E, Dieterich DT, Esposito SP, Bach N, Klion F, Tobias H, Antignano L, Brown RS Jr, Gabbaizadeh D, Geders J, Levendoglu H. Interferon alfa-2b and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol 2004; 99: 1700-5.

  209. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-a2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-75.

  210. Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A, Michielsen PP, Bellobuono A, Chemello L, Pastore G, Chen DS, Brouwer JT. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 1999; 117: 408-13.

  211. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman SV, Fried MW, Rasenack J, Sarrazin C, Jensen DM, Lin A, Hoffman JH, Sedarati F. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003; 39: 106-11.

  212. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002; 36(Suppl 1): S128-S134.

  213. Camma C, Giunta M, Chemello L, Alberti A, Toyoda H, Trepo C, Marcellin P, Zahm F, Schalm S, Craxi A. Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30: 801-7.

  214. Myers RP, Poynard T. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev 2002: CD003617.

  215. Saracco G, Olivero A, Ciancio A, Carenzi S, Smedile A, Cariti G, Andreoni M, Orsi PG, Biglino A, Tabone M, Roffi L, Croce G, Manca A, Tappero G, Ciccone G, Rizzetto M. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology 2002; 36: 959-66.

  216. Min AD, Jones JL, Esposito S, Lebovics E, Jacobson IM, Klion FM, Goldman IS, Geders JM, Tobias H, Bodian C, Bodenheimer HCJ. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. Am J Gastroenterol 2001; 96: 1143-9.

  217. Marco VD, Almasio P, Vaccaro A, Ferraro D, Parisi P, Cataldo M, Di Stefano R, Craxi A. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. J Hepatol 2000; 33: 456-62.

  218. Enriquez J, Gallego A, Torras X, Perez-Olmeda T, Diago M, Soriano V, Lujan MS, Garcia-Samaniego J. Retreatment for 24 vs. 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat 2000; 7: 403-8.

  219. Barbaro G, Di Lorenzo G, Belloni G, Ferrari L, Paiano A, Del Poggio P, Bacca D, Fruttaldo L, Mongio F, Francavilla R, Scotto G, Grisorio B, Calleri G, Annese M, Barelli A, Rocchetto P, Rizzo G, Gualandi G, Poltronieri I, Barbarini G. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. Am J Med 1999; 107: 112-18.

  220. Shiffman ML, Hofmann CM, Sterling RK, Luketic VA, Contos MJ, Sanyal AJ. A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response. J Infect Dis 2001; 184: 405-9.

  221. Jacobson IM, Ahmed F, Russo MW, Brown RSJ, Lebovics E, Min A, Esposito S, Brau N, Tobias H, Klion F, Bini E, Brodsky N, Rovner D, Brass C, NY PEG-Intron Study Group. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C. A trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results (abstr) Gastroenterology 2003; 124(Suppl 1): A714.

  222. Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, Sulkowski MS, Goodman SN. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon. JAMA 2001; 285: 193-9.

  223. Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 231-40.

  224. Shiffman ML, Hofmann CM, Gabbay J, Luketic VA, Sterling RK, Sanyal AJ, Contos MJ, Ryan MJ, Yoshida C, Rustgi V. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group. Am J Gastroenterol 2000; 95: 2928-35.

  225. Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci 1996; 41: 1248-55.

  226. Quin JW. Interferon therapy for acute hepatitis C viral infection, a review by meta-analysis. Aust N Z J Med 1997; 27: 611-17.

  227. Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, Grunewald K, Patsch J. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 1996; 41(Suppl): 81S-85S.

  228. Fabris P, Tositti G, Giordani MT, Infantolino D, de Lalla F. Three times weekly versus daily dose alpha-interferon treatment in patients with acute hepatitis C. Am J Gastroenterol 2002; 97: 492-3.

  229. Calleri G, Colombatto P, Gozzelino M, Chieppa F, Romano P, Delmastro B, Macor A, Cariti G, Brunetto MR, Grillone W, Bonino F. Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial. Ital J Gastroenterol Hepatol 1998; 30: 181-4.

  230. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-7.

  231. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-8.

  232. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, Ishibashi H, Kashiwaga S. Short-term inteferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004; 39: 1213-19.

  233. Alberti A, Boccato S, Vario A, Benvegnù L. Therapy of acute hepatitis C. Hepatology 2002; 36(Suppl 1): S195-S200.

  234. Wedemeyer H, Jackel E, Wiegand J, Cornberg M, Manns MP. Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C. Hepatology 2004; 39: 1201-3.

  235. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, Tawil AA, Fehr JJ, Khalifa KES, Madwar MM, Koziel MJ. Pegylated interferon a therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39: 1721-31.

  236. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, Monterroso ER, Garfein RS. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155: 645-53.

  237. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211-14.

  238. Neri S, Bruno CM, Abate G, Ierna D, Mauceri B, Cilio D, Bordonaro F, Pulvirenti D, Italiano C, Caruso L. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002; 24: 1627-35.

  239. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67: 117-23.

  240. Backmund M, Meyer K, von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-93.

  241. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H. Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res 2002; 8: 45-9.

  242. Brillanti S, Masci C, Siringo S, Di Febo G, Miglioli M, Barbara L. Serological and histological aspects of hepatitis C virus infection in alcoholic patients. J Hepatol 1991; 13: 347-50.

  243. Wiley TE, McCarthy M, Breidi L, Layden TJ. Impact of alcohol on the histologica and clinical progression of hepatitis C infection. Hepatology 1998; 28: 805-9.

  244. Bellentani S, Pozzato G, Saccoccio G, Crovatto M, Croce LS, Mazzoran L, Masutti F, Cristianini G, Tiribelli C. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999; 44: 874-80.

  245. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-a treatment in hepatitis C virus. Hepatology 2004; 39: 880-90.

  246. Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, Ito S, Fujiwara K. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91: 1374-9.

  247. Okazaki T, Yoshihara H, Suzuki K, Yamada Y, Tsujimura T, Kawano K, Abe H. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol 1994; 29: 1039-43.

  248. Tabone M, Sidoli L, Laudi C, Pellegrino S, Rocca G, Della Monica P, Fracchia M, Galatola G, Molinaro GC, Arico S, Pera A. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 2002; 9: 288-94.

  249. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30: 787-93.

  250. Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, Turner JR, Janisse JJ, Massanari M, Mutchnick MG. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001; 8: 264-9.

  251. De Maria N, Colantoni A, Idilman R, Friedlander L, Harig J, Van Thiel DH. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology 2002; 49: 788-92.

  252. Theodore D, Shiffman ML, Sterling RK, Bruno CJ, Weinstein J, Crippin JS, Garcia G, Wright TL, Conjeevaram H, Reddy RK, Nolte FS, Fried MW. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. Dig Dis Sci 2003; 48: 140-5.

  253. McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J, International Hepatitis Interventional Therapy Group (HIT). The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000; 119: 1317-23.

  254. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2004; 350: 2265-71.

  255. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 1702-8.

  256. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 1983; 85: 439-62.

  257. Brettler DB, Alter HJ, Dienstag JL, Forsberg AD, Levine PH. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood 1990; 76: 254-6.

  258. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual cotransmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991; 115: 764-8.

  259. Fried MW, Peter J, Hoots K, Gaglio PJ, Talbut D, Davis PC, Key NS, White GC, Lindblad L, Rickles FR, Abshire TC. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 2002; 36: 967-72.

  260. Schulman S, Grillner L. Antibodies against hepatitis C in a population of Swedish hemophiliacs and heterosexual partners. Scand J Infect Dis 1990; 22: 393-7.

  261. Stevens CE, Silbert JA, Miller DR, Dienstag JL, Purcell RH, Szmuness W. Serologic evidence of hepatitis A and B virus infections in thalassemia patients: a retrospective study. Transfusion 1978; 18: 356-60.

  262. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, Locarnini S. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol 2002; 97: 982-7.

  263. Donohue SM, Wonke B, Hoffbrand AV, Reittie J, Ganeshaguru K, Scheuer PJ, Brown D, Dusheiko G. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major. Br J Haematol 1993; 83: 491-7.

  264. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, Faa G, Diana G, Dessi C, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994; 125: 123-8.

  265. Spiliopoulou I, Repanti M, Katinakis S, Karana-Ginopoulou A, Papanastasiou DA. Response to interferon alfa-2b therapy in mutitransfused children with beta-thalassemia and chronic hepatitis C. Eur J Clin Microbiol Infect Dis 1999; 18: 709-15.

  266. Di Marco V, Lo Iacono O, Almasio P, Ciaccio C, Capra M, Rizzo M, Malizia R, Maggio A, Fabiano C, Barbaria F, Craxi A. Long term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood 1997; 90: 2207-12.

  267. Telfer PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoff-brand AV, Wonke B. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalas-saemic patients. Br J Haematol 1997; 98: 850-5.

  268. Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol 2002; 117: 755-8.

  269. Hanley JP, Jarvis LM, Andrew J, Dennis R, Hayes PC, Piris J, Lee R, Simmonds P, Ludlam CA. Interferon treatment for chronic hepatitis C infection in hemophiliacs-influence of virus load, genotype, and liver pathology on response. Blood 1996; 87: 1704-9.

  270. Rumi MG, Santagostino E, Morfini M, Gringeri A, Tagariello G, Chistolini A, Pontisso P, Tagger A, Colombo M, Mannucci PM. A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. Blood 1997; 89: 3529-33.

  271. Laursen AL, Scheibel E, Ingerslev J, Clausen NC, Wantzin P, Ostergaard L, Schou G, Black FT, Krogsgaard K. Alpha interferon therapy in Danish haemophiliac patients with chronic hepatitis C: results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon- alpha-2b treatment. Haemophilia 1998; 4: 25-32.

  272. Franchini M, Tagliaferri A, Rossetti G, Capra F, Veneri D, de Maria E, Pattacini C, Aprili G, Gandini G. Interferon and ribavirin in HIV-negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment. Haemophilia 2002; 8: 794-7.

  273. Makris M, Preston FE, Triger DR, Underwood JC, Westlake L, Adelman MI. A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. Blood 1991; 78: 1672-7.

  274. Makris M, Baglin T, Dusheiko G, Giangrande PL, Lee CA, Ludlam CA, Preston FE, Watson HG, Wilde JT, Winter M. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001; 7: 339-45.

  275. Ko JS, Choe YH, Kim EJ, Lee EH, Jang JJ, Seo JK. Interferon-alpha treatment of chronic hepatitis C in children with hemophilia. J Pediatr Gastroenterol Nutr 2001; 32: 41-4.

  276. Shields PL, Mutimer DJ, Muir D, Skidmore S, Britnell T, Roberts A, Wilde JT. Combined alpha interferon and ribavirin for the treatment of hepatitis C in patients with hereditary bleeding disorders. Br J Haematol 2000; 108: 254-8.

  277. Sauleda S, Esteban JI, Altisent C, Puig L, Esteban R, Guardia J. Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C. Thromb Haemost 2000; 83: 807-10.

  278. Schwimmer JB, Balistreri WF. Transmission, natural history, and treatment of hepatitis C virus infection in the pediatric population. Semin Liver Dis 2000; 20: 37-46.

  279. Jonas MM. Children with hepatitis C. Hepatology 2002; 36(Suppl. 1): S173-S178.

  280. Jonas MM. Treatment of chronic hepatitis C in pediatric patients. Clin Liver Dis 1999; 3: 855-67.

  281. Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34: 52-8.

  282. Gentil MA, Rocha JL, Rodriguez-Algarra G, Pereira P, Lopez R, Bernal G, Munoz J, Naranjo M, Mateos J. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999; 14: 2455-60.

  283. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257–63.

  284. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512-16.

  285. Chan TM, Lok AS, Cheng IK, Ng IO. Chronic hepatitis C after renal transplantation. Treatment with alpha-interferon. Transplantation 1993; 56: 1095-8.

  286. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P. Pharmacokinetics of al-phaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-8.

  287. Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-15.

  288. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10.

  289. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, Degott C, Carnot F, Riffaud PC, Chevret S. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 1017-23.

  290. Fernandez JL, Rendo P, del Pino N, Viola L. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists’ Group for the Study of HCV Infection. J Viral Hepat 1997; 4: 113-19.

  291. Izopet J, Rostaing L, Moussion F, Alric L, Dubois M, That HT, Payen JL, Duffaut M, Durand D, Suc JM, Puel J. High rate of hepatitis C virus clearance in hemodialysis patients after interferon- alpha therapy. J Infect Dis 1997; 176: 1614-17.

  292. Campistol JM, Esforzado N, Martinez J, Rosello L, Veciana L, Modol J, Casellas J, Pons M, de Las Cuevas X, Piera J, Oliva JA, Costa J, Barrera JM, Bruguera M. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 2704-9.

  293. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Perez JL, Guerrero L, Gonzalez MT, Andres E, Gil-Vernet S, Casais LA. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001; 96: 1170-7.

  294. Gursoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 2001; 8: 70-7.

  295. Hanrotel C, Toupance O, Lavaud S, Thiefin G, Brodard V, Ingrand D, Diebold MD, Wynckel A, Chanard J. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001; 88: 120-6.

  296. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 2001; 8: 287-92.

  297. Dienstag JL, Bhan AK, Alter HJ, Feinstone SM, Purcell RH. Circulating immune complexes in non-A, non-B hepatitis: possible masking of viral antigen. Lancet 1979; 1: 1265-7.

  298. Adinolfi LE, Utili R, Zampino R, Ragone E, Mormone G, Ruggiero G. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia. Eur J Gastroenterol Hepatol 1997; 9: 1067-72.

  299. Polzien F, Schott P, Mihm S, Ramadori G, Hartmann H. Interfer-on-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia. J Hepatol 1997; 27: 63-71.

  300. Cresta P, Musset L, Cacoub P, Frangeul L, Vitour D, Poynard T, Opolon P, Nguyen DT, Golliot F, Piette JC, Huraux JM, Lunel F. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 1999; 45: 122-8.

  301. Mazzaro C, Panarello G, Carniello S, Faelli A, Mazzi G, Crovatto M, Baracetti S, Nascimben F, Zorat F, Pozzato G, Faccini L, Campanacci L. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. Dig Liver Dis 2000; 32: 708-15.

  302. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, Sabo E, Tsykounov I, Naschitz JE, Yeshurun D. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000; 27: 2172-8.

  303. Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD. Long-term efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001; 28: 2466-73.

  304. Alric L, Plaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J, Ronco P, Piette JC, Cacoub P. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43: 617-23.

  305. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, Willson R. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-70.

  306. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, Zilio P, Vernocchi A, Massazza M, Vendramin G, Tanzi E, Zanetti A. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-6.

  307. Bonomo L, Casato M, Afeltra A, Caccavo D. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 1987; 83: 726-30.

  308. Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, Marrocchi ME, Di Pietro E, La Villa G, Laffi G, Gentilini P. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002; 137: 571-80.

  309. Mazzaro C, Franzin F, Tulissi P, Pussini E, Crovatto M, Carniello GS, Efremov DG, Burrone O, Santini G, Pozzato G. Regression of monoclonal B-cell expansion in patients affected by mnixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 1996; 77: 2604-13.

  310. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36(Suppl. 1): S201-S209.

  311. Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Current Hepat Rep 2002; 1: 16-22.

  312. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199-206.

  313. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected patient. Clin Liver Dis 2003; 7: 179-94.

  314. Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, Myers RP, Morlat P, Pialoux G, Pol S, Cacoub P. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-9.

  315. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, Yoffe B. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240-7.

  316. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, Mc-Cabe RE, Wood KC, Holmberg SD. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36: 363-7.

  317. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 1999; 179: 1254-8.

  318. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J. Care of patients with chronic hepatitis C and HIV coinfection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-28.

  319. Perez-Olmeda M, Nunez M, Romero M, Gonzalez J, Castro A, Arribas JR, Pedreira J, Barreiro P, Garcia-Samaniego J, Martin-Carbonero L, Jimenez-Nacher I, Soriano V. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17: 1023-8.

  320. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.

  321. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Ceron D, Degott C, Cacoub P, Perronne C, ANRS HCO2-RIBAVIC Study Team. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.

  322. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.

  323. Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, Bargallo X, García-Criado A, de Lazzari E, Larrousse M, León A, Loncá M, Milinkovic A, Gatell JM, Mallolas J. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27-F36.

  324. Albert A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palú G, Reiss P, Thiebault R, Weiland O, Yazdanpanah Y, Zeuzem S, the ECC Jury. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-24.

  325. Di Martino V, Thevenot T, Boyer N, Cazals-Hatem D, Degott C, Valla D, Marcellin P. HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. AIDS 2002; 16: 441-5.

  326. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochon-drial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-1.

  327. Kottilil S, Polis MA, Kivacs JA. HIV infection, hepatitis C infection, and HAART: hard clinical choices. JAMA 2004; 292: 243-50.

  328. Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE, AIDS Clinical Trials Group 383 Study. Immune recovery is associated with persistent rise in HCV RNA, infrequent liver test flares, and is not impaired by HCV in co-infected subjects. AIDS 2002; 16: 1915-23.

  329. Wright TL. Liver transplantation for chronic hepatitis C viral infection. Gastroenterol Clin North Am 1993; 22: 231-42.

  330. Johnson MW, Washburn K, Freeman RB, FitzMaurice SE, Dienstag J, Basgoz N, Jenkins RL, Cosimi B. Hepatitis C viral infection in liver transplantation. Arch Surg 1996; 131: 284-91.

  331. Féray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, Reynes M, Okamoto H, Bismuth H, Brechot C. Influence of the genotype of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108: 1088-96.

  332. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-20.

  333. Féray C, Caccamo L, Alexander GJM, Ducot B, Gugenheim J, Casanovas T, Loinaz C, Gigou M, Burra P, Barkhout L, Esteban R, Bizzolon T, Lerut J, Minello-Franza A, Bernard P-H, Nachbaur K, Botta-Fridlund D, Bismuth H, Schalm SW, Samuel D, European Concerted Action on Viral Hepatitis (EUROHEP) Group. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117: 619-25.

  334. Charlton M. Hepatitis C infection in liver transplantation. Am J Transpl 2001; 1: 197-203.

  335. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8(Suppl. 1): S14-S18.

  336. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.

  337. McTaggart RA, Terrault NA, Vardanian AJ, Bostrom A, Feng S. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl 2004; 10: 975-85.

  338. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, Garcia-Herola A, Olaso V, De Juan M, Gobernado M, Mir J, Berenguer J. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following liver transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-6.

  339. Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196-9.

  340. Everson GT. Impact of immunosuppressive therapy on recur-rence of hepatitis C. Liver Transpl 2002; 8(Suppl. 1): S19-S27.

  341. Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V, San-Juan F, Gobernado M, Mir J, Berenguer J. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28: 756-63.

  342. Braun M, Vierling JM. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transpl 2003; 9: S79-S89.

  343. Doughty AL, Spenser JD, Cossart YE, McGaughan GW. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Transpl Surg 1998; 4: 15-21.

  344. Cotler SJ, Taylor SL, Gretch DR, Bronner MP, Rozk R, Perkins JD, Carithers RLJ. Hyperbilirubinemia and cholestatic liver injury in hepatitis C-infected liver transplant recipients. Am J Gastroenterol 2000; 95: 753-9.

  345. Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, Roberts J, Wilber J, Sheridan P, Urdea M. Interferon-a therapy for hepatitis C infection after liver transplantation. Hepatology 1994; 20: 773-9.

  346. Gane EJ, Lo S-K, Riordan SM, Portmann BC, Lau JYN, Naoumov NV, Williams R. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27: 1403-7.

  347. Sheiner PA. Hepatitis C after liver transplantation. Semin Liver Dis 2000; 20: 201-9.

  348. Gane E. Treatment of recurrent hepatitis C. Liver Transpl 2002; 8(Suppl. 1): S28-S37.

  349. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, Cohard M, Reynes M, Chevallier M, Ducerf C, Baulieux J, Geffner M, Albrecht JK, Bismuth H, Trepo C. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-50.

  350. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, Pouyet M, Trepo C. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500-4.

  351. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, Bissoli F, Ceriani R, Ballare M, Massari M, Trischitta C, Fiore P, Orlandi A, Morini L, Mattioli M, Oldani S, Cesana B, Fiorelli G. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol 2002; 97: 1204-10.

  352. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS, Ferguson R, Krawitt E, Banner B, Bacon BR. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000; 32: 135-8.

  353. Mangia A, Minerva N, Annese M, Leandro G, Villani MR, Santoro R, Carretta V, Bacca D, Giangaspero A, Bisceglia M, Ventrella F, Dell’Erba G, Andriulli A. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001; 33: 989-93.

  354. Brillanti S, Foli M, Di Tomaso M, Gramantieri L, Masci C, Bolondi L. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital J Gastroenterol Hepatol 1999; 31: 130-4.

  355. Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, Hopf U. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32: 835-41.

  356. Tabone M, Laudi C, Delmastro B, Biglino A, Andreoni M, Chieppa F, Bonardi R, Cariti G, Cusumano S, Brunello F, Calleri G, Manca A, Della Monica P, Sidoli L, Rizzetto M, Pera A. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol 2001; 35: 517-21.

  357. Younossi ZM, Mullen KD, Zakko W, Hodnick S, Brand E, Barnes DS, Carey WD, McCullough AC, Easley K, Boparai N, Gramlich T. A randomized, double-blind controlled trial of interferon alpha-outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 1999; 46: 3216-22.

  358. Shiratori Y, Nakata R, Shimizu N, Katada H, Hisamitsu S, Yasuda E, Matsumura M, Narita T, Kawada K, Omata M. High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group. Dig Dis Sci 2000; 45: 2414-21.

  359. Suzuki F, Chayama K, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen. J Gastroenterol 2001; 36: 242-7.

  360. Katayama K, Kasahara A, Sasaki Y, Kashiwagi T, Naito M, Masuzawa M, Katoh M, Yoshihara H, Kamada T, Mukuda T, Hijioka T, Hori M, Hayashi N. Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance. J Viral Hepat 2001; 8: 180-5.

  361. Muir AJ, Sylvestre PB, Rockey DC. Interferon gamma-1b for the treatment of chronic HCV infection (abstr). Gastroenterology 2003; 124: A718.

  362. McHutchison JG, Giannelli G, Nyberg L, Blatt LM, Waite K, Mischkot P, Pianko S, Conrad A, Grint P. A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. J Interferon Cytokine Res 1999; 19: 1265-70.

  363. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000; 118: 655-60.

  364. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu LX, Cabrera R, Davis GL. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammaatory effect. Hepatology 2003; 38: 859-68.

  365. Moscarella S, Buzzelli G, Romanelli RG, Monti M, Giannini C, Careccia G, Marrocchi EM, Zignego AL. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. Liver 1998; 18: 366-9.

  366. Sherman KE, Sjogren M, Creager RL, Damiano MA, Freeman S, Lewey S, Davis D, Root S, Weber FL, Ishak KG, Goodman ZD. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 1998; 27: 1128-35.

  367. Teran JC, Mullen KD, Hoofnagle JH, McCullough AJ. Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-a. Hepatology 1994; 19: 849-56.

  368. Alri L, Duffaut M, Selves J, Sandre K, Mularczyck M, Izopet J, Desmorat H, Bureau C, Chaouche N, Dalbergue B, Vinel JP. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J Hepatol 2001; 35: 272-8.

  369. Kalmowitz BD, Afdhal NH. Maintenance therapies for hepatitis C. Current Hepat Rep 2004; 3: 23-9.

  370. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clinical Trials 2005; 25: 472-92.

  371. Afdhal NH, Freilich B, Black M, Levine RW, Brass C. Comparison of therapy with PEG-Intron 0.5 mcg/kg versus colchicine 0.6 mg bid in 250 patients with cirrhosis and HCV: Interim data from COPILOT (abstr). Hepatology 2002; 36: 312A.

  372. Coon JT, Ernst E. Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review. J Hepatol 2004; 40: 491-500.

  373. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology 2001; 34: 596-3.

  374. Liu J, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol 2003; 98: 538-44.




2020     |     www.medigraphic.com